

The table below shares some of the most important research presented at ASCO/EHA 2025. We've highlighted the key findings that could make a real difference in treatment options for people with myeloma, no matter where they are in their journey.

Treatment Intervention	Abbreviation	Study Population	Key Takeaway	Clinical Trial Name
Sarclisa (isatuximab) (on body delivery system) + Pomalyst (pomalidomide) + Dexamethasone	Isa (SC)-Pd	Relapsed/Refractory Myeloma Patients	Sarclisa on body delivery system works just as well as IV delivery with similar side effect profile	IRAKLIA
Sarclisa (isatuximab) + Kyprolis (carfilzomib) + Revlimid (Lenalidomide) + Dexamethasone	Isa-KRd	High Risk Newly Diagnosed Patients (Genetic alterations)	Quadruplet therapies can offer a deep and enduring response for newly diagnosed, high-risk patients	GMMG-CONCEPT
Sarclisa (isatuximab) + Velcade (bortezomib) + Revlimid (Lenalidomide) + Dexamethasone	Isa-VRd	High Risk Newly Diagnosed Patients (Genetic alterations)		IMROZ
Sarclisa (isatuximab) + Kyprolis (carfilzomib) + Revlimid (Lenalidomide) + Dexamethasone	Isa-KRd	Newly Diagnosed Patients	Patients on IsaKRD had deep response rates with or without a stem cell transplant	MIDAS
Darzalex (daratumumab) + Velcade (bortezomib) + Revlimid (Lenalidomide) + Dexamethasone	D-VRd	Newly Diagnosed Patients (Frail or transplant ineligible)	Patients without a stem cell transplant had deep and enduring responses to D-VRd treatment	CEPHEUS
JNJ-79635322 Trispecific Antibody	JNJ-Trispecific	Relapsed/Refractory Patients	Trispecific antibodies may be safe and effective for patients who are refractory to many myeloma therapies	JNJ-79635322
ISB-2001 Trispecific Antibody	ISB-Trispecific	Relapsed/Refractory Patients		ISB-2001
Blenrep (belantamab mafodotin) + Pomalyst (pomalidomide) + Dexamethasone	BPd	Relapsed/Refractory Patients	New Blenrep combination is more effective than standard of care therapy (PVd) for relapsed/refractory patients	DREAMM-8
Linvoseltamab + Velcade (bortezomib)	LV	Relapsed/Refractory Patients	Combining a proteasome inhibitor with linvoseltamab can make this bispecific antibody more effective	LINKER-MM2
Linvoseltamab + Kyprolis (carfilzomib)	LK	Relapsed/Refractory Patients		LINKER-MM2
Carvykti (cilta-cel) CAR T-Cell Therapy	Cilta-cel	Relapsed/Refractory Patients	CAR T-cell therapy may help control the disease for up to 5 years, even in patients with high-risk myeloma	CARTITUDE-1